Acute Myeloid Leukemia (AML) Awareness Day: Evolving Treatment Directions Oncology Data Advisor

In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including:
• Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors
• The role of measurable residual disease (MRD) testing
• Considerations for pediatric transplant and cellular therapy
• Words of hope for patients undergoing treatment for AML

Additionally, they answered live questions from the audience, including:
• Do you have any first-line treatment recommendations for patients with a KMT2A mutation?
• When do recommend that patients participate in a clinical trial?

Take a listen to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML!